Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96F07
UPID:
CYFP2_HUMAN
Alternative names:
p53-inducible protein 121
Alternative UPACC:
Q96F07; A6NLT2; D3DQJ3; Q53EN5; Q9NTK4; Q9ULQ2; Q9UN29
Background:
Cytoplasmic FMR1-interacting protein 2, also known as p53-inducible protein 121, plays a crucial role in T-cell adhesion and p53/TP53-dependent apoptosis. It is a key component of the WAVE1 complex, essential for BDNF-NTRK2 endocytic trafficking and signaling from early endosomes. This protein does not bind RNA.
Therapeutic significance:
The protein is implicated in Developmental and Epileptic Encephalopathy 65 (DEE65), a severe early-onset epilepsy with neurodevelopmental impairment. Understanding the role of Cytoplasmic FMR1-interacting protein 2 could open doors to potential therapeutic strategies for DEE65.